Geron Corporation's Q2 2025: Unraveling Contradictions in Patient Demand, Physician Intent, and Revenue Strategies

Patient demand growth sustainability, physician awareness and prescribing intent, revenue growth and sales strategy, KOL engagement and market research, dynamics of RYTELO prescribing and demand growth are the key contradictions discussed in Geron Corporation's latest 2025Q2 earnings call.



RYTELO Revenue Growth:
- Geron Corporation reported RYTELO net revenues of $49 million for Q2 2025, representing an approximately 24% increase over the first quarter.
- The growth was driven by increased demand from new patient starts and execution of enhanced commercial strategies.

Patient Demand and Awareness:
- The company saw approximately 30% of RYTELO new patient starts in first and second lines by May 2025, indicating a shift towards earlier line use.
- This trend is attributed to increased awareness and confidence among healthcare professionals following aligned educational efforts.

Sales Force Expansion and Impact:
- Geron expanded its commercial sales force by over 20% and doubled the size of its medical affairs organization.
- This expansion is expected to enhance KOL support and advocacy, contributing to improved RYTELO prescription rates and patient demand.

IMpactMF Trial Enrollment:
- The IMpactMF Phase III trial in relapsed/refractory myelofibrosis is now over 95% enrolled, and enrollment is expected to complete by year-end.
- The trial's success is driven by strong enrollment momentum, which is crucial for the potential expansion of imetelstat in this indication.